date:May 21, 2012
and should deliver healthy margins.
Doing more add-on acquisitions in nutrition makes sense for DSM. Smaller deals such as this are easier to integrate and it being non-listed results in DSM paying a reasonable multiple for such a high-margin business, said ING analyst Fabian Smeets.
There is a strategic fit, there should be growth opportunities, and the deal is EPS (earnings per share) accretive ... in 2013 already.
ONC forecast sales of about C$190m (147m) for 2012 with EBITDA earnings u